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Background. A multidimensional, brief, and ﬂexible stroke-speciﬁc health-related quality of life (HRQOL) measure is still needed.
The aim was to develop a shortened version of the HRQOLISP-102, a multiculturally generated measure with excellent psycho-
metric properties. Methods. Participants included 100 (Ibadan, Nigeria) and 103 (Berlin, Germany) stroke patients compared to
100 (Ibadan) and 50 (Berlin) apparently healthy adults. Using standard protocol, the 26-item version was generated, consisting of
therapeutically relevant physical, psychological, cognitive, and ecosocial domains. Criterion validity of the HRQOLISP-26 was
determined using Bland-Altman statistics. “Known groups” validity was assessed using NIHSS, stroke levity score, and modiﬁed
Rankinscale.Results.HRQOLISP-26waseasilyinterpretableandprecisewithnosigniﬁcantﬂoor/ceilingeﬀect.Itcanbecompleted
within7minutes.Itshowedgoodcontent,construct,“knowngroups,”andcriterionvalidity.Itdemonstratedgoodinternalconsis-
tency (α = 0.81, 0.89) and test-retest reliability. Conclusions. HRQOLISP-26 is novel, brief, multiculturally-valid, and ﬂexible for
routine assessment of HRQOL in stroke patients.
1.Introduction
The number of stroke patients is increasing particularly in
low-andmedium-incomecountries[1,2].Theultimategoal
of rehabilitation of stroke patients is to improve their quality
of life. Health-related quality of life (HRQOL) measures are
therefore crucial for the routine evaluation of the patient’s
rehabilitation needs, prognosis, and response to various
therapies (including physical, psychological, cognitive, and
occupational therapies).
The 102-item HRQOL in stroke patients (HRQOLISP) is
a multiculturally generated, multifaceted, well-validated,
holistic measure with excellent psychometric properties [3–
5]. It consists of two spheres with seven domains. Its physical
sphere comprises the therapeutically relevant physical, psy-
choemotional, cognitive and ecosocial domains. However, its
length may make it unattractive for routine clinical use.
Short versions of other HRQOL measures, including the
SSQOL-12, SIS-16, and QLASS-19, are brief but have inad-
equate content validity, due to exclusion of therapeutically
relevant multidimensional structure central to the HRQOL
concept [3, 6–9]. The SIS-16 assesses only the physical do-
main, the SSQOL-12 assesses only two dimensions [7] while
the QLASS has no distinct cognitive and social domains [8].
A shortened version of the HRQOLISP-102, the
HRQOLISP-40, is designed for studies of internal adaptation
and disability disparity in stroke patients [10, 11]. However,
a shorter version still, is necessary for routine clinical use and
evaluation of various interventions. Such a shorter version
should be administrable within a few minutes so as to reduce
respondent burden. However, it should remain suﬃciently
multidimensional to obviate the need for combination with
several other instruments which would still constitute more
burden for the patient.
The aims of this study were to develop a ﬂexible shorter
version of the HRQOLISP suitable for regular assessment of
all routinely crucial domains of HRQOL and to determine
if its psychometric robustness, particularly its multidimen-
sional construct and “known groups” validity, is retained
despite further item reduction.2 ISRN Neurology
2. Methods
2.1. Design and Participants. In line with convention, data
obtained from previous validation studies of the HRQOLISP
were utilized [6, 7, 12]. This included 353 respondents (100
stroke patients and 100 apparently healthy adults [13, 14]
in Ibadan; and 103 stroke and 50 controls in Berlin). As is
done conventionally, apparently healthy controls were used
for comparison as any other group of respondents will have
impairedHRQOL[13,14].Furthermore,within-groupcom-
parison was conducted across stroke severity strata. Those
excluded from the study were patients who had ambiguous
diagnosis of stroke or other medical conditions that were
neither risk factors for nor complications of stroke but could
interfere with HRQOL. Ethical permission was obtained
from the ethical committees of the University of Ibadan and
Charite Universitaetmedizin Berlin.
2.2. Measures. Stroke levity scale (SLS) was applied as an
index of stroke severity. The SLS correlates signiﬁcantly to
the NIHSS (rho =− 0.79, P<0.0001) and is a valid measure
of stroke severity which can be used in illiterate populations
[15]. Stroke was classiﬁed using the WHO stroke scale [16–
19] and brain CT. Disability was assessed with the modiﬁed
Rankin scale (mRS) while HRQOL was measured by the
102-item HRQOLISP instrument whose characteristics are
described in detail elsewhere [5]. Assessments were made at
least one month after stroke to consecutive stroke patients.
The HRQOLISP has been shown to be both interviewer-
and self-administrable with mode of administration having
no signiﬁcant impact on scores [11]. In Ibadan, a subset of
stroke patients (20) had repeat interview within 2 days after
the ﬁrst assessment by the same interviewer. In Berlin, a reas-
sessment was similarly conducted in 10 patients, within one
week.
2.3. Data Analysis. Data analysis was carried out using gold
standard methods widely reported in HRQOL literature [14,
20–22]. From data generated in both cities, using a com-
bination of factor analysis (item-total correlation, item-fac-
tor loading), ﬂoor and ceiling eﬀects, skewness, test-retest
weighted-kappa statistics and item contribution to content
and construct validity, the best 26 items were chosen out of a
total of 63 initial items in the physical sphere [21]( A p p e n -
dices I and II). Thereafter the score for each HRQOLISP-
26 and HRQOLISP-63 domain was generated by Likert’s
method which facilitates interpretation and interindividual
comparisons. The domain scores were transformed into a
scale with a maximum score of 100 (best health) each. The
overall scores were generated by ﬁnding the arithmetic mean
of the domain scores.
2.4. A Priori Statements. To establish discriminant validity,
stroke patients are expected to have worse HRQOL proﬁle
than healthy controls. To establish “known groups” validity,
there should be signiﬁcant diﬀerences in mean HRQOL
scores across mRS, SLS and NIHSS strata. To establish cri-
terion validity, there should be good agreement and strong
(ρ ≥ 0.60) correlation between the corresponding domains
and overall scores of the HRQOLISP-26 and HRQOLISP-63
[21].
2.5. Psychometric Analysis of HRQOLISP-26. Discriminant
validity was assessed between the test and control popula-
tions using Student’s t-test and ANCOVA. “Known groups”
validity was evaluated by comparing responses from patients
with various severities of stroke using Kruskal-Wallis test
[20]. Criterion validity was assessed using correlation statis-
tics and Bland-Altman plots comparing the HRQOLISP 26
to the HRQOLISP-63 as a gold standard [7, 23]. The per-
centages of variance of the HRQOLISP-63 scores that could
be explained by the 26-item version scores were computed
[7, 23]. At the individual level, the limits of agreement
(±1.96×SDdiﬀerence)werecalculatedusingtheBland-Altman
procedure [7, 23]. Agreements between the corresponding
domain and overall scores of the 26-item and 63-item ver-
sions were examined by computing the mean diﬀerences, the
95%conﬁdenceinterval,andtheeﬀectsizes.Eﬀectsizeswere
obtained by dividing the mean diﬀerences by the standard
deviation (SD) of the corresponding 63-item HRQOLISP
score [7]. The conventional interpretation of eﬀect sizes is
0.2 is small, 0.5 is medium, and 0.8 is large [7, 23].
Internal consistency reliability was determined by calcu-
lating Cronbach’s coeﬃcients [20]. For test-retest reliability,
weightedkappastatisticswascalculated[24].Flooreﬀectwas
deﬁned as the presence of greater than 20% of the respon-
dents scoring <10% [21]. Ceiling eﬀect was acknowledged if
the percentage of those with domain score >90% was greater
than20%oftherespondents[21].Thestatisticallysigniﬁcant
two-tailedP value(alpha)wassetat<0.05.Datawasanalyzed
using the SPSS software.
3. Results
The characteristics of the respondents are presented in
Table S1 (see supplementary material available online at doi:
10.5402/2011/295096). They were drawn from many ethnic
groups (including Yoruba, Igbo, Hausa) in Nigeria, a devel-
opingcountry,andseveralethnicgroups(includingGerman,
Turkish, Russian, Spanish, Korean) in Germany, an industri-
alized country.
3.1. Development of the HRQOLISP-26. The best 26 items
were chosen out of a total of 63 initial items in the physical
sphere of the HRQOLISP-102. Most of the items had very
strong item-domain correlation (0.70 to 0.90). Four items
with moderate item-domain correlation but pivotal contri-
bution to the content validity and test-retest reliability were
retained. Given that in Germany and Nigeria, the 102-item
v e r s i o nt o o ka b o u t2 7m i n u t e st oc o m p l e t e ,t h ee s t i m a t e d
completion time of the HRQOLISP-26 is 7 minutes. It com-
prises four therapeutically relevant domains.
3.2. Criterion Validity of the HRQOLISP-26. In both coun-
tries, the HRQOLISP-26 domain and overall scores corre-
lated strongly (rho = 0.90 to 0.97, P<0.000001) to the cor-
responding HRQOLISP-63 scores and explained 82 to 95%
of the variance of the long version (Table 1). The overallISRN Neurology 3
Table 1: Criterion validity of the HRQOLISP-26.
Berlin
HRQOLISP-
63 mean,
SD
HRQOLISP-
26 mean,
SD
Diﬀ. in mean
scores
Eﬀect size of
diﬀ. in mean
scores∗
Mean diﬀ. in individual scores
(95% CI) between
corresponding HRQOLISP-63
and HRQOLISP-26 domains†
Spearman
rho‡
Explained
variance of
domain by
short version
(%)
Physical 65.1, 13.0 68.9, 17.5 −3.80 0.29 −3.91 (−5.26 to −2.56) 0.941§ 88
Psychological 74.1, 12.3 69.4. 15.0 4.70 0.38 4.93 (4.01 to 5.85) 0.943§ 92
Cognitive 75.5, 13.0 75.9, 14.1 −0.40 0.03 −0.47 (−1.39 to 0.45) 0.938§ 91
Ecosocial 68.3, 9.1 68.6, 12.9 −0.30 0.03 −0.24 (−1.36 to 0.88) 0.917§ 85
HRQOLISP-26 70.8, 9.6 70.7,12.2 0.10 0.01 0.07 (−0.64to0.78) 0.968§ 95
Ibadan
Physical 73.9, 14.1 72.5, 15.8 1.40 0.10 −0.01 (−1.83 to 1.81) 0.925§ 92
Psychological 74.4, 13.5 69.0, 16.9 5.40 0.40 5.65 (4.42 to 6.88) 0.962§ 92
Cognitive 71.7, 13.2 74.5, 15.4 −2.80 0.21 −2.91 (−4.26 to −1.56) 0.899§ 82
Ecosocial 69.2, 10.1 71.2, 12.5 −2.00 0.20 −2.01 (−3.30 to −0.72) 0.916§ 86
HRQOLISP-26 71.3, 10.2 69.0,14.1 2.30 0.23 1.42 (−0.60to3.44) 0.961§ 93
∗Calculated by dividing diﬀerence in mean by SD of HRQOL-637.
†Obtained by substracting HRQOLISP-26 score from HRQOLISP-63 scores.
‡Correlation between HRQOLISP-26 and corresponding HRQOLISP-63 domains.
§P<0.000001.
HRQOLISP-26 score explained 93% of the variance of the
long version in Ibadan, and 95% in Berlin (Table 1). At
the individual level, the mean diﬀerences between the
HRQOLISP-26 and HRQOLISP-63 scores were not signiﬁ-
cant (Table 1). The limits of agreement were small (below
10%) with small-to-medium eﬀect sizes (Table 1). The
Bland-Altman plots (Figure 1 and Figure S1) for the domain
and total scores show that in both countries, the diﬀerences
in individual scores were distributed evenly about the mean
line across the full range of the mean scores.
At the population level, the diﬀerences in mean scores
between the short and the long versions were negligible
(Table 1). The biggest diﬀerence was 5.4 on a scale of 0 to 100
in the domains, some of which had nearly identical scores.
For the total scores, the diﬀerences were 2.3% in Ibadan,
0.1% in Berlin. The eﬀect sizes of the diﬀerences were 0.23
for Ibadan and 0.01 for Berlin.
3.3. Construct and “Known Groups” Validity. The HRQO-
LISP-26wasabletodiscriminatebetweenthestrokeandcon-
trol groups in all domains in both cities even after adjusting
for possible confounders (0.0001 <P<0.024, Table 2).
A crossSLSandmRSstratainIbadanaswellasSLS,mRS,and
NIHSS strata in Berlin, the HRQOLISP-26 showed signiﬁ-
cant “known groups” and construct validity in all domains
(0.0001 <P<0.042) except the cognitive domain in Berlin
(Table 2, Figure 2 and Figure S2). However, the cognitive
domain demonstrated discriminant validity between stroke
and control groups in Berlin and Ibadan, and “known
groups” validity across NIHSS strata in Berlin (P = 0.034)
and across SLS, mRS strata in Ibadan. The overall HRQO-
LISP-26 score demonstrated “known groups” and construct
validity across SLS, mRS in both cities and NIHSS strata in
Berlin (Table 2, Figure 2 and Figure S2).
3.4. Reliability, Floor, and Ceiling Eﬀects. Results of the KMO
test showed satisfactory sampling adequacy (≥0.60) and
Bartlett’s test of sphericity was signiﬁcant for all models.
One-factorsolutionexplained >50%ofthevarianceformost
domains in both cities (Table 3). Floor eﬀect was absent in
all domains in both countries. Ceiling eﬀect was absent in
all domains in Berlin and Ibadan except the physical domain
in Ibadan (Table 3). However, only 2% scored 100% in the
physical domain in Ibadan, while in both cities <2% scored
100% overall. The Cronbach’s alpha was ≥0.7 in all domains
inbothcities(Table 3).Itwas0.81(Berlin)and0.89(Ibadan)
for the total HRQOLISP-26 score.
4. Discussion
Despite previous research eﬀorts, the need remains for a
multidimensional but brief, patient-centered but therapeu-
tically relevant, multiculturally-valid but easily interpretable,
ﬂexiblebutreliablestroke-speciﬁcHRQOLmeasure[3,9,25,
26]. Such a balance has not been meticulously attained by
preexisting measures. Generic measures are not designed for
speciﬁc diseases and are thus not sensitive to subtle patient-
speciﬁc and disease-speciﬁc changes in HRQOL [3, 4, 27].
Furthermore, because they lack adequate content validity for
stroke, generic measures are not suitable for routine clinical
use or clinical trials in stroke [3, 4, 27].
To reduce respondent burden, improve acceptability, and
routine utility, the trend is towards the development of con-
cise measures. Examples of stroke-speciﬁc brief measures in-
clude the SIS-16, the SSQOL-12, and QLASS-19. While these
measures are brief and user friendly, they sacriﬁced multi-
dimensionality and content validity for brevity. Such pau-
cidimensionalmeasuresareoftencombinedinseriestocover4 ISRN Neurology
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(d) Cognitive domain Berlin
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(e) Ecosocial domain Berlin
Figure 1: Bland-Altman plots of the HRQOLISP-26 versus HRQOLISP-63 (Berlin). Bland-Altman plots of the diﬀerences between the
63-item physical sphere of the HRQOLISP (initial) and the HRQOLISP-26 (shorter) scores related to the mean of the HRQOLISP-63 and
HRQOLISP-26 scores for domains and total score in Berlin. The x-axes represent levels of HRQOL calculated as the means of the initial and
shorter version scores and the y-axes represent the diﬀerences between scores on initial and shorter versions. The horizontal lines represent
the mean diﬀerence.ISRN Neurology 5
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Table 2: Construct validity statistics for HRQOLISP-26 in both countries.
Comparison between stroke and control groups Kruskal-Wallis statistics of HRQOL
scores across stroke strata
Berlin
HRQOL
scores in
stroke patients
mean, SD
n = 103
HRQOL
scores in
controls
mean, SD
n = 50
t
values
two-tailed
P values
ANCOVA
(adjusted for
age, gender,
and SEC)
F, P values
SLS strata
K-W † χ2,
P values
mRS
K-W † χ2,
P values
NIHSS
strata
K-W † χ2,
P values
Physical domain 68.99, 17.49 93.37, 3.86 −9.729 0.00∗ 25.759, 0.00∗ 44.4, 0.00∗ 69.2, 0.00∗ 54.4, 0.00∗
Psychological
domain 69.35, 14.97 82.45, 10.98 −5.504 0.00∗ 8.443, 0.00∗ 16.1, 0.00∗ 16.3, 0.003 19.6, 0.00∗
Cognitive
domain 75.98, 15.07 84.16, 9.70 −3.498 0.001 3.877, 0.005 5.54, 0.063 8.3, 0.080 6.7, 0.034
Ecosocial
domain 68.64, 12.92 84.03, 8.33 −7.675 0.00∗ 22.453, 0.00∗ 18.1, 0.00∗ 39.2, 0.00∗ 30.3, 0.00
HRQOLISP-26 70.74, 12.17 86.00, 6.49 −8.301 0.00∗ 19.102, 0.00∗ 28.2, 0.00∗ 44.3, 0.00∗ 36.3, 0.00∗
Ibadan n = 100 n = 100
Physical
domain 72.5, 15.8 91.3, 7.6 −8.19 0.00∗ 10.443, 0.00∗ 18.9, 0.042 23.2, 0.00∗
Psychological
domain 69.0, 16.9 81.6, 11.4 −5.55 0.00∗ 5.768, 0.001 28.0, 0.003 21.7, 0.005
Cognitive
domain 74.5, 15.4 84.0, 11.8 −4.69 0.00∗ 6.085, 0.001 26.9, 0.005 27.8, 0.00∗
Ecosocial
domain 71.2, 12.5 78.2, 9.6 −3.931 0.00∗ 6.840, 0.00∗ 23.5, 0.015 25.0, 0.00∗
HRQOLISP-26 68.9, 14.1 81.6, 8.4 −4.677 0.00∗ 5.487, 0.024 6.8, 0.03 12.0, 0.003
∗P<0.00001, K-W †: Kruskal-Wallis test.
SEC: socioeconomic class was computed using an aggregate of 3 variables (educational level, occupational strata, and average income).
NIHSS: National Institute of Health Stroke Scale.
SLS: stroke levity score, mRS: modiﬁed Rankin scale.
Table 3: Reliability statistics of the HRQOLISP-26.
Berlin
Number of items
in original
version
Number of items
in shorter version
(SV)
Percent
explanation of SV
by 1-factor
solution
KMO,
Bartlett P
Floor, ceiling
eﬀects∗
(domains)
Weighted
kappa
test-retest†
(items)
Cronbach’s
alpha for
shorter
version
Physical domain 16 7 55 0.83, 0.000 0,10 1.00 0.82
Psychological
domain 12 7 54 0.85, 0.000 0,4 1.00 0.81
Cognitive domain 12 5 59 0.75, 0.000 0,8 0.71–1.00 0.82
Ecosocial domain 23 7 41 0.73, 0.000 0,3 0.69–1.00 0.76
HRQOLISP-26 63 26 65 0.76, 0.000 0,3 0.69–1.00 0.81
Ibadan
Physical domain 16 7 50 0.74, 0.000 0,29 0.86–1.00 0.81
Psychological
domain 12 7 52 0.83, 0.000 0,12 0.67–1.00 0.84
Cognitive domain 12 5 62 0.73, 0.000 0,20 0.76–1.00 0.84
Ecosocial domain 23 7 39 0.67, 0.000 0,8 0.85–1.000 0.70
HRQOLISP-26 63 26 75 0.76, 0.000 0,8 0.67–1.00 0.89
∗Percentage of respondents with scores below 10% (ﬂoor) and above 90% (ceiling).
†Only 1 item had weighted kappa <0.75 in Ibadan, 2 items had weighted kappa <0.75 in Berlin.ISRN Neurology 7
all relevant dimensions thus subjecting patients to an unac-
ceptable burden which reduces the overall frequency and
reliability of responses [28].
The HRQOLISP is the ﬁrst multicultural-generated, hol-
istic, patient-centred, and multidimensional stroke-speciﬁc
measure[10,29,30].Theessenceofthisstudywastoshorten
itwithoutcompromisingitstherapeuticallyrelevantmultidi-
mensionality, content validity, and reliability.
4.1. Content and Criterion Validity of the HRQOLISP-26.
Content validity is an assessment of how well the domains of
interest are sampled. The HRQOLISP-26 contains items re-
commended for HRQOL measures [31, 32] distributed in
therapeutically relevant domains. The physical domain cor-
responds to physiotherapy, psychological domain to psycho-
therapy, cognitive domain to speech, language and cognitive
therapy, and ecosocial domain to occupational therapy and
social reintegration. However, the spiritual sphere covered in
the HRQOLISP-40 and HRQOLISP-102 is excluded. There-
fore, for studies of internal adaptation and disability dispar-
ity the HRQOLISP-40 or HRQOLISP-102 is better [10, 11].
In both countries and cultural settings, with negligible
mean diﬀerences between the HRQOLISP-26 and HRQO-
LISP-63 domains and total scores, at the individual and pop-
ulation levels, the HRQOLISP-26 has good criterion validity.
This is further corroborated by the very strong correlation
and percentage explained variance, small eﬀect sizes and
limits of agreement, and the favourable Bland-Altman plots.
Therefore, in multicultural settings, for all types of stroke,
the HRQOLISP-26 has suﬃcient criterion validity to be used
insteadoftheHRQOLISP-63asawholeorfortheassessment
of the individual domains.
Although the SSQOL-12 which has physical and psycho-
social domains, has good criterion validity, it does not have
distinct cognitive and ecosocial domains. Likewise the SIS-
16 is dimension-speciﬁc, covering only the physical domain
for which it has better “known groups” validity than the
Barthelindex[6].Thus,toassessforalltherequireddomains
using the SIS, the 59-item version, which is too long for
routine use, would be necessary. Unlike the SIS-16 [6], the
QLASS [8], and SASIP-30 [12], because the HRQOLISP-26
is comprehensive and covers all therapeutically relevant do-
mains,itneednotbecombinedwithothermeasurestoassess
HRQOL in stroke patients.
Therefore, in terms of striking a balance between content
validity and brevity, the HRQOLISP-26 is better.
4.2. Precision, “Known Groups,” and Construct Validity. Pre-
cision is concerned with the number and accuracy of dis-
tinctions made by a measure, that is, precision of response
categories or of numerical values [25, 26]. This is also indi-
cated by the capacity of the measure to report the most
favourable or poorest health states that is the paucity of ﬂoor
or ceiling eﬀects [25, 26]. The absence of signiﬁcant ceiling
and ﬂoor eﬀects across the domains and overall scores in
both countries coupled with the good construct and “known
groups” validity as demonstrated by the Kruskal-Wallis sta-
tistics(Table S2)[33]predictsgoodsensitivitytochange[34,
35].Typicalofdisease-speciﬁcmeasurestappingdisease-spe-
ciﬁc concepts, it would be able to assess the worst and the
best health states possible and detect small improvements
and deteriorations [34, 35]. It would be useful in assessing
the impact of therapeutic and rehabilitative interventions in
stroke patients. However, prospective studies are needed to
conﬁrm this.
Furthermore, in both settings, the HRQOLISP-26 was
able to detect diﬀerences in HRQOL scores across mRS
strata, particularly the physical and ecosocial domains to
which it has similar construct. The overlaps in the boxplots
for the cognitive and psychological domains by mRS strata is
because the mRS is not a cognitive or psychological model.
However, comparison of the HRQOLISP’s psychological
facet to corresponding SF-36 facets demonstrated good con-
vergent validity [11].
Therefore, despite item reduction, the HRQOLISP-26
remains precise, and has good “known groups” and con-
struct validity across its domains and as a whole.
4.3. Reliability. In both countries, the HRQOLISP-26 ful-
ﬁlled Nunnally’s criterion for internal consistency reliability
with coeﬃcients similar to those for SIS, SSQOL, and
NEWSQOL and better than the SASIP-30 [12]. The con-
ceptual model for its structure was corroborated by the fact
that most domains ﬁtted appreciably to a one-factor model
[14, 20–22, 33, 36]. In both cities, the single-rater test-retest
kappa statistics were excellent (>0.75) for most items (25 in
Ibadan and 24 in Berlin) and good [24] for the remainder
(Table 3) despite the slight diﬀerence in the timing of the
repeat administration. Larger studies are required to assess
its interrater reliability.
4.4.Brevity,Flexibility,Interpretability,andAcceptability. The
HRQOLISP-26 can be completed within 7 minutes which
saves 20 minutes compared to the HRQOLISP-102. This can
be further shortened by selecting and combining only the
domains that are appropriate to the design of a study [25,
26]. The possibility to combine the various domains of the
HRQOLISP-26, which has been individually and collectively
validated, is a unique ﬂexibility of the HRQOLISP-26 which
distinguishes it from other stroke-speciﬁc measures.
Furthermore, unlike the SSQOL which is measured on a
s c a l eo f0t o5[ 7], the ordinal scale of 0 to 100 also improves
interpretability. Therefore the unique brevity, ﬂexibility, and
interpretability of the HRQOLISP-26 would encourage its
routine utility and acceptability in comparison to preexisting
measures. This could be further improved by the ongoing
development of a computer-based automated scoring and
HRQOLISP wheel for prospective tracking of HRQOL in
stroke patients.
4.5. Strengths, Limitations, and Future Directions. The HRQ-
OLISP-26 is the shortest multidimensional, multiculturally
generated and transnationally-validated, precise stroke-spe-
ciﬁc HRQOL measure. Although, in accordance with con-
ventional practice [6, 7, 12], existing data was used in its
development, and criterion validation [6, 7, 12], this is not
a setback. This is because even though theoretically, actual
answers on the HRQOLISP-26 may diﬀer from answers8 ISRN Neurology
retrieved for these items from the long HRQOLISP (as a
patient’s answers might be aﬀected by other questions) [7];
concurrent application of the short and long versions is less
feasible and may introduce the same bias that one wishes to
avoid: inﬂuence on response by previous questions [7].
Notwithstanding, the HRQOLISP-26 is currently being
used in a prospective international randomized control trial
that would yield further information about its psychometric
properties. Other prospective studies are also ongoing in
diﬀerent parts of Africa and Europe to further demonstrate
its robust psychometric properties in diverse cultural set-
tings. Also desirable are more extensive proxy-validation and
additional external validation of the cognitive domain by
cross-culturally validated cognitive scales which are applica-
b l er e g a r d l e s so fl i t e r a c yl e v e l .
4.6. Conclusions and Implications. The HRQOLISP-26 is a
novel, brief, multiculturally valid, and reliable stroke-speciﬁc
measure. It is precise, interpretable, and ﬂexible, comprising
therapeutically relevant domains. It has good criterion, con-
tent, “known groups,” and construct validity. It is therefore
recommended for routine clinical and research use.
Acknowledgments
The author acknowledges the DAAD (German Academic
Exchange Program), which sponsored his stay in Germany;
members of staﬀ of the University College Hospital, Ibadan;
the Charit´ e, Median Klinik; the Evangelisches Geriatrisches
Zentrum; the Sport Gesundheit Park, Berlin, who contribu-
ted to the success of the study.
References
[1] V. L. Feigin, C. M. M. Lawes, D. A. Bennett, and C. S. Ander-
son, “Stroke epidemiology: a review of population-based
studies of incidence, prevalence, and case-fatality in the late
20th century,” Lancet Neurology, vol. 2, no. 1, pp. 43–53, 2003.
[2] V.L.Feigin,C.M.Lawes,D.A.Bennett,S.L.Barker-Collo,and
V. Parag, “Worldwide stroke incidence and early case fatality
reported in 56 population-based studies: systematic review,”
The Lancet Neurology, vol. 8, no. 4, pp. 355–369, 2009.
[3] M. O. Owolabi, “Which is more valid for stroke patients:
generic or stroke-speciﬁc quality of life measures?” Neuroepi-
demiology, vol. 34, no. 1, pp. 8–12, 2010.
[4] M. O. Owolabi, “RQOLISP is more valid than SF-36,” in Pro-
ceedings of the 6th World Congress of Neurorehabilitation,p p .
177–182, Vienna, Austria, March 2010.
[5] M. O. Owolabi and A. Ogunniyi, “Proﬁle of health-related
quality of life in Nigerian stroke survivors,” European Journal
of Neurology, vol. 16, no. 1, pp. 54–62, 2009.
[ 6 ]P .W .D u n c a n ,S .M .L a i ,R .K .B o d e ,S .P e r e r a ,a n dJ .
DeRosa,“Strokeimpactscale-16:abriefassessmentofphysical
function,” Neurology, vol. 60, no. 2, pp. 291–296, 2003.
[7] M. W. M. Post, H. Boosman, M. M. van Zandvoort, P. E.
Passier,G.J.Rinkel,andJ.M.Visser-Meily,“Developmentand
validation of a short version of the Stroke Speciﬁc Quality of
Life Scale,” Journal of Neurology, Neurosurgery and Psychiatry,
vol. 82, no. 3, pp. 283–286, 2011.
[8] M. Russell, M. Dempster, and M. Donnelly, “Measuring
Health-Related Quality of Life after ischemic stroke: a brief
tool,” Applied Research in Quality of Life, vol. 6, no. 1, pp. 14–
51, 2011.
[9] K. L. Salter, M. B. Moses, N. C. Foley, and R. W. Teasell,
“Health-related quality of life after stroke: what are we mea-
suring?” International Journal of Rehabilitation Research, vol.
31, no. 2, pp. 111–117, 2008.
[10] M. O. Owolabi, “Application of the seed of life model: concept
of quality of life and the disability paradox,” Journal of Alter-
native Medicine Research, vol. 1, pp. 401–408, 2009.
[11] M.OjoOwolabi,“PsychometricpropertiesoftheHRQOLISP-
40: a novel, shortened multiculturally valid holistic stroke
measure,” Neurorehabilitation and Neural Repair, vol. 24, no.
9, pp. 814–825, 2010.
[ 1 2 ]A .v a nS t r a t e n ,R .J .d eH a a n ,M .L i m b u r g ,J .S c h u l i n g ,P .M .
Bossuyt, and G. A. M. van den Bos, “A stroke-adapted 30-item
version of the sickness impact proﬁle to assess quality of life
(SA-SIP30),” Stroke, vol. 28, no. 11, pp. 2155–2161, 1997.
[13] M. L. Hackett, J. R. Duncan, C. S. Anderson, J. B. Broad, and
R. Bonita, “Health-related quality of life among long-term
survivors of stroke: results from the Auckland stroke study,
1991-1992,” Stroke, vol. 31, no. 2, pp. 440–447, 2000.
[14] R. B. King, “Quality of life after stroke,” Stroke, vol. 27, no. 9,
pp. 1467–1472, 1996.
[15] M. O. Owolabi and T. Platz, “Proposing the stroke levity scale:
a valid, reliable, simple, and time-saving measure of stroke
severity,” European Journal of Neurology,v o l .1 5 ,n o .6 ,p p .
627–633, 2008.
[16] World Health Organization, Cerebrovascular Disorders: a Clin-
ical and Research Classiﬁcation, World Health Organization,
Geneva, Switzerland, 1978.
[17] M. D. Connor, R. Walker, G. Modi, and C. P. Warlow, “Burden
of stroke in black populations in sub-Saharan Africa,” Lancet
Neurology, vol. 6, no. 3, pp. 269–278, 2007.
[18] M. O. Owolabi, J. H. Bower, and A. Ogunniyi, “Mapping
Africa’s way into prominence in the ﬁeld of neurology,” Ar-
chives of Neurology, vol. 64, no. 12, pp. 1696–1700, 2007.
[19] S. A. Ogun, O. Oluwole, B. Fatade, A. O. Ogunseyinde, F. I.
Ojini, and K. A. Odusote, “Comparison of Siriraj Stroke Score
and the WHO criteria in the clinical classiﬁcation of stroke
subtypes,” African Journal of Medicine and Medical Sciences,
vol. 31, no. 1, pp. 13–16, 2002.
[20] P .W .Duncan,D .W allace,S.M.Lai,D .J ohnson,S.Embretson,
and L. J. Laster, “The stroke impact scale version 2.0: evalua-
tion of reliability, validity, and sensitivity to change,” Stroke,
vol. 30, no. 10, pp. 2131–2140, 1999.
[21] K. Hilari, S. Byng, D. L. Lamping, and S. C. Smith, “Stroke
and aphasia quality of life scale-39 (SAQOL-39): evaluation of
acceptability, reliability, and validity,” Stroke,v o l .3 4 ,n o .8 ,p p .
1944–1950, 2003.
[22] S.M.Lai,S.Studenski,P.W.Duncan,andS.Perera,“Persisting
consequences of stroke measured by the stroke impact scale,”
Stroke, vol. 33, no. 7, pp. 1840–1844, 2002.
[23] J. M. Bland and D. G. Altman, “Statistical methods for assess-
ingagreementbetweentwomethodsofclinicalmeasurement,”
Lancet, vol. 1, no. 8476, pp. 307–310, 1986.
[24] C. M. Whelley-Wilson and G. C. Newman, “A stroke scale for
emergency triage,” Journal of Stroke and Cerebrovascular Di-
seases, vol. 13, no. 6, pp. 247–253, 2004.
[ 2 5 ]D .B u c k ,A .J a c o b y ,A .M a s s e y ,a n dG .F o r d ,“ E v a l u a t i o no f
measures used to assess quality of life after stroke,” Stroke, vol.
31, no. 8, pp. 2004–2010, 2000.
[26] I. J. Higginson and A. J. Carr, “Measuring quality of life: using
quality of life measures in the clinical setting,” British Medical
Journal, vol. 322, no. 7297, pp. 1297–1300, 2001.ISRN Neurology 9
[27] L. S. Williams, M. Weinberger, L. E. Harris, D. O. Clark, and J.
Biller, “Development of a stroke-speciﬁc quality of life scale,”
Stroke, vol. 30, no. 7, pp. 1362–1369, 1999.
[28] L. D’Olhaberriague, I. Litvan, P. Mitsias, and H. H. Mansbach,
“A reappraisal of reliability and validity studies in stroke,”
Stroke, vol. 27, no. 12, pp. 2331–2336, 1996.
[29] M. O. Owolabi, “Health-Related Quality of Life (HRQOL)
measures: there are still many unanswered questions about
human life,” TheScientiﬁcWorldJournal, vol. 8, pp. 357–363,
2008.
[30] M. O. Owolabi, “Health related quality of life (HRQOL) and
the seed of life model,” Journal of Alternative Medicine Re-
search, vol. 1, pp. 375–382, 2009.
[31] P. W. Duncan, H. S. Jorgensen, and D. T. Wade, “Outcome
measures in acute stroke trials: a systematic review and some
recommendations to improve practice,” Stroke, vol. 31, no. 6,
pp. 1429–1438, 2000.
[32] J. Orley and W. Kuyken, Quality of Life Assessment: Interna-
tional Perspectives, Springer, Paris, France, 1993.
[33] D. Buck, A. Jacoby, A. Massey, N. Steen, A. Sharma, and G. A.
Ford, “Development and validation of NEWSQOL, the new-
castle stroke-speciﬁc quality of life measure,” Cerebrovascular
Diseases, vol. 17, no. 2-3, pp. 143–152, 2004.
[34] P. J. Dorman, M. Dennis, and P. Sandercock, “How do scores
on the EuroQol relate to scores on the SF-36 after stroke?”
Stroke, vol. 30, no. 10, pp. 2146–2151, 1999.
[ 3 5 ]J .C .H o b a r t ,L .S .W i l l i a m s ,K .M o r a n ,a n dA .J .T h o m p s o n ,
“Quality of life measurement after stroke: uses and abuses of
the SF-36,” Stroke, vol. 33, no. 5, pp. 1348–1356, 2002.
[36] S. M. Lai, S. Perera, P. W. Duncan, and R. Bode, “Physical
and social functioning after stroke: comparison of the stroke
impact scale and Short Form-36,” Stroke,v o l .3 4 ,n o .2 ,p p .
488–493, 2003.